Home › NDC Lookup › RxCUI directory › RxCUI 1245262

Mifepristone 300 MG Oral Tablet — RxCUI 1245262

RxNorm drug concept · Semantic clinical drug
RxCUI 1245262 Semantic clinical drug · SCD ● Current RxNorm concept 3 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1245262
Official nameMifepristone 300 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped3
Package NDCs mapped4
Reported Medicaid activity (SDUD)1,415 prescriptions · 15 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Mifepristone (Mifeprex): what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Great question — this one confuses a lot of people. Mifepristone isn't a standard diabetes drug. It's only used when Cushing's syndrome is what's causing your blood sugar to be hig...
  • Why is mifepristone being prescribed for my blood sugar if I already know I have diabetes?
  • This is really important. Mifepristone blocks progesterone, which is the hormone your body needs to sustain a pregnancy — so if you became pregnant while taking it, the pregnancy w...
  • I'm a woman of childbearing age. What do I need to know about birth control while on this?
📖 Read our full Mifepristone (Mifeprex) guide →

🕸️ Concept Web — How Mifepristone 300 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Mifepristone 300 MG Oral Tablet RxCUI 1245262

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Mifepristone 6964
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Korlym 1245263
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Mifepristone Oral Tablet 374644
    • Mifepristone Oral Product 1164723
    • Mifepristone Pill 1164724
    • Mifepristone Oral Tablet [Korlym] 1245265
    • Korlym Oral Product 1245266
    • Korlym Pill 1245267
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Mifepristone 300 MG SCDC · 1245261
  • Mifepristone Oral Tablet SCDF · 374644
  • Mifepristone Oral Product SCDG · 1164723
  • Mifepristone Pill SCDG · 1164724

Brand-Name Concepts

  • Mifepristone 300 MG Oral Tablet [Korlym] SBD · 1245268
  • Mifepristone 300 MG [Korlym] SBDC · 1245264
  • Mifepristone Oral Tablet [Korlym] SBDF · 1245265
  • Korlym Oral Product SBDG · 1245266
  • Korlym Pill SBDG · 1245267
  • Korlym BN · 1245263

📦 FDA Products & Package NDCs

3 products · 4 package NDCs
4 package NDCs map to RxCUI 1245262 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00591-4390-96 28 TABLET, FILM COATED in 1 BOTTLE (0591-4390-96) Mifepristone Actavis Pharma, Inc. 2024-01-19
76346-0073-01 28 TABLET in 1 BOTTLE (76346-073-01) Korlym Corcept Therapeutics Incorporated 2012-02-17
76346-0073-02 280 TABLET in 1 BOTTLE (76346-073-02) Korlym Corcept Therapeutics Incorporated 2012-02-17
76346-0654-03 280 TABLET in 1 BOTTLE (76346-654-03) Mifepristone Corcept Therapeutics Incorporated 2024-05-28
Observed labelers: Corcept Therapeutics Incorporated (3) · Actavis Pharma, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.